[Lymphoproliferative disease in pediatric liver transplantation].
Post-Transplant Lymphoproliferative Disorders are due to continuous B-lymphocyte proliferation induced by Epstein-Barr Virus (EBV) infection which is recovered in 88% of transplanted patients. These disorders may present clinically as lymphadenopathic syndrome with lymphoid tissue hyperplasia, systemic as a mononucleosis-like syndrome and lymphomatous syndrome, indistinguishable from non-Hodgkin's lymphoma. We present 10 patients of PTLD classified as 7 lymphadenopathic, 1 systemic (this patient had both syndromes) and 3 lymphomatous tumours. At present, PTLD treatment consists of surgical removal of accessible masses or post-chemotherapy (ChT) tumour rests, total or partial withdrawal of immunosuppressive drugs and ChT following the Sociéte Française d'Oncologie Pédiatrique (SFOP) protocol for non-Hodgkin's lymphoma.
Martínez Ibáñez
V
V
De Diego
M
M
Allende
H
H
Ruiz-Marcellán
C
C
de Torres
I
I
Español
T
T
Marqués
A
A
Boix-Ochoa
J
J
D000293:Adolescent; D002648:Child; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy; D016031:Liver Transplantation / Q000009:adverse effects; D008232:Lymphoproliferative Disorders / Q000209:etiology* / Q000628:therapy; D008297:Male; D011183:Postoperative Complications; D013997:Time Factors
Enfermedad linfoproliferativa en el trasplante hepático pediátrico.